QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

TECHTICKER

Bio-Techne Corp.

BULLISH stock

Congress has disclosed 8 buys and 10 sells of TECH (Bio-Techne Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

8
Buy
10
Sell
-2
Net
5
Active politicians

Round-trip watch Still on the books

Members who disclosed buying TECH and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Rohit Khanna 2026-03-30 $51.89 $72.69 +40.1% in profit

Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
104.2
≈ in line with Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$72.69 ÷ $0.70 = 104.2
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
5.42
▲ pricier than Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$72.69 ÷ $13.42 = 5.42
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
31.93
▲ pricier than Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($11.4B − $0.3B net cash) ÷ $0.3B = $11.2B ÷ $0.3B = 31.93
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

Legislation Related Legislation

Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

18 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
April McClain Delaney House SELL ◆ insider convergence Child 2026-04-08 23 days -0.3% $1K–$15K
<0.1% of NW
0.8 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2026-03-30 3 days +2.1% $1K–$15K 49.3 ↗ filing
April McClain Delaney House SELL ◆ insider convergence Child 2026-03-26 6 days +1.5% $1K–$15K
<0.1% of NW
0.7 ↗ filing
April McClain Delaney House SELL ◆ insider convergence Child 2026-02-24 6 days +0.4% $1K–$15K
<0.1% of NW
0.7 ↗ filing
April McClain Delaney House SELL ◆ insider convergence Child 2026-01-28 4 days -2.2% $1K–$15K
<0.1% of NW
0.7 ↗ filing
April McClain Delaney House BUY Child 2025-12-05 27 days -4.7% $1K–$15K
<0.1% of NW
0.8 ↗ filing
April McClain Delaney House BUY Child 2025-12-02 30 days -6.6% $1K–$15K
<0.1% of NW
1.0 ↗ filing
April McClain Delaney House BUY ◆ insider divergence Child 2025-10-22 10 days -1.9% $1K–$15K
<0.1% of NW
4.2 ↗ filing
April McClain Delaney House SELL ◆ insider convergence · moderate Child 2025-08-01 31 days -0.3% $1K–$15K
<0.1% of NW
7.4 ↗ filing
April McClain Delaney House SELL ◆ insider convergence Child 2025-05-26 36 days +11.3% $1K–$15K
<0.1% of NW
12.9 ↗ filing
April McClain Delaney House BUY ◆ insider divergence Child 2025-04-29 2 days -1.7% $1K–$15K
<0.1% of NW
25.8 ↗ filing
April McClain Delaney House BUY ◆ insider divergence Child 2025-04-09 22 days -8.2% $1K–$15K
<0.1% of NW
62.3 ↗ filing
Rob Bresnahan House SELL ◆ insider convergence Self · JP Morgan Brokerage Account 2025-04-08 0 days 0.0% $1K–$15K
0.2% of NW
33.6 ↗ filing
Julie Johnson House SELL ◆ insider convergence Joint · Merrill Lynch Tax Efficient Core 2025-04-01 35 days -16.8% $1K–$15K
<0.1% of NW
66.4 ↗ filing
Rob Bresnahan House BUY ◆ insider divergence Self · JP Morgan Brokerage Account 2025-02-25 0 days 0.0% $1K–$15K
0.2% of NW
64.4 ↗ filing
Rohit Khanna House BUY OCR Child 2023-12-05 30 days — $1K–$15K 75.9 ↗ filing
Greg Gianforte House SELL Joint 2020-10-13 6 days — $1K–$15K 40.4 ↗ filing
Greg Gianforte House SELL Joint 2019-01-24 4 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in TECH — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

8
Congress trades with insider convergence
5
…with insider divergence
14
Insider open-market trades

Of the congressional trades in TECH, 8 coincided with corporate insiders moving the same way within 60 days, and 5 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-05-08 Herr Amy E. Director SELL $320K ↗ EDGAR
2026-02-17 Herr Amy E. Director SELL $117K ↗ EDGAR
2025-08-25 BAUMGARTNER ROBERT V Director SELL $958K ↗ EDGAR
2025-08-25 Nusse Roeland Director SELL $960K ↗ EDGAR
2025-06-09 Herr Amy E. Director SELL $64K ↗ EDGAR
2025-02-14 Herr Amy E. Director SELL $123K ↗ EDGAR
2025-01-27 Kelderman Kim C-suite SELL $906K ↗ EDGAR
2025-01-27 Kelderman Kim C-suite SELL $129K ↗ EDGAR
2024-08-08 BAUMGARTNER ROBERT V Director SELL $1.2M ↗ EDGAR
2024-05-14 HIGGINS JOHN L Director SELL $335K ↗ EDGAR
2024-03-07 Nusse Roeland Director SELL $801K ↗ EDGAR
2023-08-30 Nusse Roeland Director SELL $718K ↗ EDGAR
2023-07-21 Kummeth Charles R. C-suite SELL 10b5-1 $7.1M ↗ EDGAR
2023-06-07 Kummeth Charles R. C-suite SELL $27K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-05-08 Herr Amy E. Director SELL $320K
Congress 2026-04-08 April McClain Delaney SELL $1K–$15K
Congress 2026-03-30 Rohit Khanna BUY $1K–$15K
Congress 2026-03-26 April McClain Delaney SELL $1K–$15K
Congress 2026-02-24 April McClain Delaney SELL $1K–$15K
◆ insider 2026-02-17 Herr Amy E. Director SELL $117K
Congress 2026-01-28 April McClain Delaney SELL $1K–$15K
Congress 2025-12-05 April McClain Delaney BUY $1K–$15K
Congress 2025-12-02 April McClain Delaney BUY $1K–$15K
Congress 2025-10-22 April McClain Delaney BUY $1K–$15K
◆ insider 2025-08-25 BAUMGARTNER ROBERT V Director SELL $958K
◆ insider 2025-08-25 Nusse Roeland Director SELL $960K
Congress 2025-08-01 April McClain Delaney SELL $1K–$15K
◆ insider 2025-06-09 Herr Amy E. Director SELL $64K
Congress 2025-05-26 April McClain Delaney SELL $1K–$15K
Congress 2025-04-29 April McClain Delaney BUY $1K–$15K
Congress 2025-04-09 April McClain Delaney BUY $1K–$15K
Congress 2025-04-08 Rob Bresnahan SELL $1K–$15K
Congress 2025-04-01 Julie Johnson SELL $1K–$15K
Congress 2025-02-25 Rob Bresnahan BUY $1K–$15K
◆ insider 2025-02-14 Herr Amy E. Director SELL $123K
◆ insider 2025-01-27 Kelderman Kim C-suite SELL $906K
◆ insider 2025-01-27 Kelderman Kim C-suite SELL $129K
◆ insider 2024-08-08 BAUMGARTNER ROBERT V Director SELL $1.2M

FAQ Common questions

How much has Congress traded TECH?

8 disclosed buys and 10 sells of TECH (Bio-Techne Corp.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade TECH?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.